[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366564-105":59,"doc-detail-366564-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pancreatic-cancer-and-benign-pancreatic-cystic-lesions-differences-in-cytokines-growth-factors-and-immunological-markers-concentrations-in-serum-and-cystic-fluid","Pancreatic Cancer and Benign Pancreatic Cystic Lesions: Differences in Cytokines, Growth Factors, and Immunological Markers Concentrations in Serum and Cystic Fluid","","Pancreatic cystic lesions can be benign or malignant, and distinguishing them is challenging despite the need to avoid risky surgery. Sixty consecutive patients undergoing pancreatic surgery due to pancreatic cancer or benign pancreatic cystic lesions were analyzed. Concentrations of 16 immunological factors were measured in both serum and cystic fluid and compared between groups. Lower PDGF-AB/BB and leptin in serum, and lower sTIE-2, osteopontin, and leptin in cystic fluid were associated with malignancy. Some marker concentrations also differed between serum and cystic fluid in cystic tumors, suggesting candidates for future biomarker development requiring larger confirmation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pancreatic-cancer-and-benign-pancreatic-cystic-lesions-differences-in-cytokines-growth-factors-and-immunological-markers-concentrations-in-serum-and-cystic-fluid/366564/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pancreatic-cancer-and-benign-pancreatic-cystic-lesions-differences-in-cytokines-growth-factors-and-immunological-markers-concentrations-in-serum-and-cystic-fluid/366564.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of this study?","Question",{"text":113,"@type":114},"To identify immunological factors measured in serum and cystic fluid that could help differentiate pancreatic cancer from benign pancreatic cystic lesions and reduce unnecessary risky interventions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients were included and what samples were analyzed?",{"text":118,"@type":114},"Sixty consecutive patients were included, and concentrations of 16 immunological factors were assessed in both serum and cystic fluid.",{"name":120,"@type":111,"acceptedAnswer":121},"Which markers were associated with pancreatic cancer?",{"text":122,"@type":114},"Lower serum PDGF-AB/BB and leptin were associated with cancer, and lower cystic fluid sTIE-2, osteopontin, and leptin were also linked to malignant lesions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366564,1790535866,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398046744996,"Article  \nPancreatic Cancer and Benign Pancreatic Cystic Lesions: Differences in Cytokines, Growth Factors, and Immunological Markers Concentrations in Serum and Cystic Fluid  \nEwa Grudzi ´nska 1, *, Paweł Szmigiel 1, Karolina Majewska 1, Sławomir Mrowiec 1 and Zenon P. Czuba 2  \nAcademic Editors: Ioannis P. Trontzasand Konstantinos Syrigos  \nReceived: 31 July 2025  \nRevised: 18 August 2025  \nAccepted: 22 August 2025  \nPublished: 26 August 2025  \nCitation: Grudzi ´nska, E.; Szmigiel, P.; Majewska, K.; Mrowiec, S.; Czuba, Z.P. Pancreatic Cancer and Benign Pancreatic Cystic Lesions: Differences in Cytokines, Growth Factors, and Immunological Markers Concentrations in Serum and Cystic Fluid. Cancers 2025, 17, 2783. [https://](https://)[ ](https://)[doi.org/10.3390/cancers17172783](doi.org/10.3390/cancers17172783)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Gastrointestinal Surgery, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; [karolina.majewska@sum.edu.pl](karolina.majewska@sum.edu.pl) (K.M.); [smrowiec@sum.edu.pl](smrowiec@sum.edu.pl) (S.M.)  \n2 Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland; [zczuba@sum.edu.pl](zczuba@sum.edu.pl)  \n* Correspondence: [ewa.grudzinska@sum.edu.pl](ewa.grudzinska@sum.edu.pl)  \nSimple Summary  \nPancreatic cystic tumors require risky surgery when malignancy is suspected. To avoid unnecessary interventions and make a precise diagnosis easier, the search for biomarkers of pancreatic cancer is ongoing. To our knowledge, there are no studies on immunological factors assessed in the cystic fluid from removed tumors. We analyzed a panel of 16 immunological factors in a group of 60 patients undergoing pancreatic surgery due to pancreatic cancer or benign pancreatic cystic lesions. We found an association between cancer and lower serum concentrations of PDGF-AB/BB and leptin. Also, lower concentrations of sTIE-2, osteopontin, and leptin in the cystic fluid were associated with malignant lesions. In patients with cystic tumors, the concentrations of some markers differed between serum and cystic fluid. The described factors present possible future biomarkers for pancreatic lesion diagnostics, and further research in larger groups of patients is required.  \nAbstract  \nBackground: Pancreatic cystic lesions may be benign and require observation or cancerous, with high mortality, requiring risky surgery. Diagnosis is often difficult, and the search for biomarkers to differentiate pancreatic cancer from other lesions is ongoing. Methods:  \n60 consecutive patients, operated on due to histopathologically confirmed pancreatic cancer or due to pancreatic cystic lesions, were analyzed. The concentrations of 16 immunological factors (sHER-2neu, sEGFR, sIL-6Ra, follistatin, FGF-basic, sVEGFR-2, PECAM-1, PDGFAB BB, prolactin, G-CSF, HGF, sTIE-2, SCF, sVEGFR-1, osteopontin, and leptin) were assessed in both serum and cystic fluid and compared between the groups. Results: Lower PDGF-AB/BB and leptin concentrations in serum, as well as lower sTIE-2, osteopontin, and leptin levels, were associated with cancer. In cystic tumors, for some factors, significant differences between cancerous and benign lesions were found when the differences in cystic fluid and serum concentrations were compared. Conclusions: PDGF-AB/BB, leptin, sTIE-2, and osteopontin, as well as the comparison of serum/cystic fluid concentrations of immunological factors, might be useful for pancreatic cystic tumor diagnosis. However, this requires confirmation in a larger study.  \nKeywords: pancreatic ca","cbCaigNyhzGkol8q","https://ap.wps.com/l/cbCaigNyhzGkol8q","pdf",1328617,15,"English","# Introduction\n# Simple Summary\n# Abstract\n# Keywords\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To identify immunological factors measured in serum and cystic fluid that could help differentiate pancreatic cancer from benign pancreatic cystic lesions and reduce unnecessary risky interventions.\"},{\"question\":\"How many patients were included and what samples were analyzed?\",\"answer\":\"Sixty consecutive patients were included, and concentrations of 16 immunological factors were assessed in both serum and cystic fluid.\"},{\"question\":\"Which markers were associated with pancreatic cancer?\",\"answer\":\"Lower serum PDGF-AB/BB and leptin were associated with cancer, and lower cystic fluid sTIE-2, osteopontin, and leptin were also linked to malignant lesions.\"}]","Pancreatic Cancer and Benign Pancreatic Cystic Lesions: Differences in Cytokines, Growth Factors, and Immunological Markers Concentrations in Serum and Cystic Fluid | PDF",1790166093,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44214dabc00f612dad367554f91b70eb.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10b573ccbded3378fcab852dab0d605c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c27bbe84f02027ff96b49f96cd7b2bb6.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48c008b65b094d41b255ed0e7b9d21ab.webp",980,1385]